Close Menu

NEW YORK – The GenomeWeb Index rose more than 6 percent in November, as several stock saw gains in the double digits.

The index outperformed the Dow Jones Industrial Average and the Nasdaq — which gained nearly 4 percent and nearly 5 percent, respectively — but underperformed the Nasdaq Biotechnology Index, which gained more than 11 percent. Individual stock performance in the GenomeWeb Index was mostly positive as 24 of the 31 stocks saw gains and seven saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Los Angeles brought and settled a civil enforcement action against the makers of an at-home test for SARS-CoV-2, NPR reports. 

The Guardian reports that Cancer Research UK is cutting its research funding by £44 million.

Technology Review examines factors affecting SARS-CoV-2 testing turnaround times.

In PNAS this week: mapping of ancient human migrations in Europe, recurrent gene fusion in breast cancer, and more.